Prevalence and Clinical Characteristics of Patients With Heart Failure With Preserved Ejection Fraction Who Meet the Obesity-Related Eligibility Criteria for Subcutaneous Incretin Receptor Agonists in Japan ― Insights From the PARACLETE Study ―

Circulation Journal 2026 Open access

Read full text
Authors: Ken Nishikawa, Sho Suzuki, Masatoshi Minamisawa, Akane Yamakawa, Shinya Hiramitsu, Katsuya Onishi, Dai Yumino, Kenji Shiino, T Ueda, Atsuhiko Kawamoto, Masato Kasahara, Shungo Hikoso
+3 more Koichiro Kuwahara, Yoshihiko Saito, on behalf of The PARACLETE Study Investigators
DOI: 10.1253/circj.cj-25-1120
Cited by: 1
References: 5

Abstract

BACKGROUND: The prevalence of patients with heart failure with preserved ejection fraction (HFpEF) who meet the insurance eligibility criteria in Japan for obesity treatment with the glucagon-like peptide-1 receptor agonist (GLP-1RA), and the dual glucose-dependent insulinotropic polypeptide and GLP-1 receptor agonist (GIP/GLP-1RA) remains unclear. METHODS AND RESULTS: This subanalysis of the PARACLETE study included compensated ambulatory patients with HFpEF. Among the 3706 patients, 654 (17.6%) were eligible for GLP-1RA and GIP/GLP-1RA. Eligible patients had more severe symptoms despite higher prescription rates of HF-related medications. CONCLUSIONS: Among patients with HFpEF in Japan, 17.6% met the insurance eligibility criteria for obesity treatment with GLP-1RA and GIP/GLP-1RA.

Fields of Study & Subjects

Diabetes Treatment and Management Heart Failure Treatment and Management Cardiovascular Function and Risk Factors

Publication details

Journal / source
Circulation Journal
Publisher
Japanese Circulation Society
Volume
90
Issue
6
Pages
745–748
Publication date
9 April 2026
Language
EN